SG10202002831RA - Bicyclic compound and use thereof for inhibiting suv39h2 - Google Patents
Bicyclic compound and use thereof for inhibiting suv39h2Info
- Publication number
- SG10202002831RA SG10202002831RA SG10202002831RA SG10202002831RA SG10202002831RA SG 10202002831R A SG10202002831R A SG 10202002831RA SG 10202002831R A SG10202002831R A SG 10202002831RA SG 10202002831R A SG10202002831R A SG 10202002831RA SG 10202002831R A SG10202002831R A SG 10202002831RA
- Authority
- SG
- Singapore
- Prior art keywords
- suv39h2
- inhibiting
- bicyclic compound
- bicyclic
- compound
- Prior art date
Links
- -1 Bicyclic compound Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234183P | 2015-09-29 | 2015-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202002831RA true SG10202002831RA (en) | 2020-05-28 |
Family
ID=58427860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202002831RA SG10202002831RA (en) | 2015-09-29 | 2016-09-12 | Bicyclic compound and use thereof for inhibiting suv39h2 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10508109B2 (ko) |
| EP (1) | EP3355699B1 (ko) |
| JP (1) | JP6827621B2 (ko) |
| KR (1) | KR20180082432A (ko) |
| CN (1) | CN108135175B (ko) |
| AU (2) | AU2016332021A1 (ko) |
| BR (1) | BR112018006005A2 (ko) |
| CA (1) | CA2999852A1 (ko) |
| DK (1) | DK3355699T3 (ko) |
| ES (1) | ES2874089T3 (ko) |
| HK (1) | HK1252428A1 (ko) |
| IL (1) | IL258328B (ko) |
| MX (1) | MX2018003903A (ko) |
| RU (1) | RU2729187C1 (ko) |
| SG (1) | SG10202002831RA (ko) |
| TW (1) | TWI696622B (ko) |
| WO (1) | WO2017058503A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115702149A (zh) * | 2020-04-30 | 2023-02-14 | 先正达农作物保护股份公司 | 具有含硫取代基的杀有害生物活性的杂环衍生物 |
| WO2022040259A1 (en) * | 2020-08-19 | 2022-02-24 | Bristol-Myers Squibb Company | Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis |
| CN113304151B (zh) * | 2021-04-15 | 2022-05-03 | 中山大学 | 一种硝基呋喃类小分子化合物在制备诱导铁死亡和/或减缓胃癌化疗耐药药物中的应用 |
| CN117924279A (zh) * | 2024-03-18 | 2024-04-26 | 中山大学 | 一种melk抑制剂及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC1673A1 (fr) | 1984-06-27 | 1986-06-03 | Wellcome Found | Derives aryliques de composes imidazoliques,leur preparation et leur emploi pour la preparation des medicaments |
| US6596731B2 (en) * | 2001-03-27 | 2003-07-22 | Hoffmann-La Roche Inc. | Substituted imidazo[1,2-A] pyridine derivatives |
| US20060194199A1 (en) | 2002-09-30 | 2006-08-31 | Oncotherapy Science, Inc. | Method for diagnosing testicular seminomas |
| TWI350373B (en) | 2004-01-23 | 2011-10-11 | Oncotherapy Science Inc | Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators |
| EP2295602B1 (en) | 2005-07-27 | 2012-07-11 | Oncotherapy Science, Inc. | Method of prognosing cancers |
| KR20100072344A (ko) * | 2007-10-26 | 2010-06-30 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
| CN101861316B (zh) * | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| FR2928922B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| DK2280706T3 (da) * | 2008-05-14 | 2013-02-04 | Otsuka Pharma Co Ltd | Lipasa-aktiverende lipoproteinsammensætninger omfattende benzenderivater |
| US8729102B2 (en) * | 2010-11-30 | 2014-05-20 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| US8975276B2 (en) * | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| WO2014177458A1 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES |
| JP6130055B2 (ja) * | 2013-05-23 | 2017-05-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 造影剤としての２−フェニルイミダゾ［１．２−ａ］ピリミジン |
| WO2014187922A1 (en) | 2013-05-24 | 2014-11-27 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| EP3778598A3 (en) * | 2013-07-02 | 2021-08-04 | Syngenta Participations Ag | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents |
-
2016
- 2016-09-12 SG SG10202002831RA patent/SG10202002831RA/en unknown
- 2016-09-12 MX MX2018003903A patent/MX2018003903A/es unknown
- 2016-09-12 EP EP16852299.3A patent/EP3355699B1/en active Active
- 2016-09-12 US US15/763,389 patent/US10508109B2/en not_active Expired - Fee Related
- 2016-09-12 CA CA2999852A patent/CA2999852A1/en not_active Abandoned
- 2016-09-12 KR KR1020187011807A patent/KR20180082432A/ko unknown
- 2016-09-12 BR BR112018006005A patent/BR112018006005A2/pt active Search and Examination
- 2016-09-12 AU AU2016332021A patent/AU2016332021A1/en not_active Abandoned
- 2016-09-12 JP JP2018516526A patent/JP6827621B2/ja active Active
- 2016-09-12 RU RU2018115695A patent/RU2729187C1/ru active
- 2016-09-12 ES ES16852299T patent/ES2874089T3/es active Active
- 2016-09-12 WO PCT/US2016/051350 patent/WO2017058503A1/en active Application Filing
- 2016-09-12 CN CN201680057033.7A patent/CN108135175B/zh not_active Expired - Fee Related
- 2016-09-12 DK DK16852299.3T patent/DK3355699T3/da active
- 2016-09-29 TW TW105131218A patent/TWI696622B/zh not_active IP Right Cessation
-
2018
- 2018-03-25 IL IL258328A patent/IL258328B/en active IP Right Grant
- 2018-09-12 HK HK18111729.5A patent/HK1252428A1/zh unknown
-
2021
- 2021-03-12 AU AU2021201573A patent/AU2021201573B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL258328A (en) | 2018-05-31 |
| US20180273529A1 (en) | 2018-09-27 |
| HK1252428A1 (zh) | 2019-05-24 |
| CN108135175A (zh) | 2018-06-08 |
| AU2016332021A1 (en) | 2018-04-19 |
| US10508109B2 (en) | 2019-12-17 |
| AU2021201573B2 (en) | 2022-02-17 |
| JP2018531244A (ja) | 2018-10-25 |
| ES2874089T3 (es) | 2021-11-04 |
| AU2021201573A1 (en) | 2021-04-01 |
| EP3355699A4 (en) | 2019-06-19 |
| DK3355699T3 (da) | 2021-06-07 |
| CN108135175B (zh) | 2021-04-06 |
| BR112018006005A2 (pt) | 2018-10-30 |
| TW201718580A (zh) | 2017-06-01 |
| RU2729187C1 (ru) | 2020-08-05 |
| TWI696622B (zh) | 2020-06-21 |
| KR20180082432A (ko) | 2018-07-18 |
| IL258328B (en) | 2021-05-31 |
| MX2018003903A (es) | 2018-09-21 |
| EP3355699A1 (en) | 2018-08-08 |
| WO2017058503A1 (en) | 2017-04-06 |
| CA2999852A1 (en) | 2017-04-06 |
| JP6827621B2 (ja) | 2021-02-10 |
| EP3355699B1 (en) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283267B (en) | Inhibitors of menin–mll interaction | |
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| PL3512850T3 (pl) | Inhibitory interakcji menina-mll | |
| ZA201804070B (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| HK1251610A1 (zh) | 用於抑制因子d的組合物和方法 | |
| HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
| HK1259422A1 (zh) | 用於抑制jak的化合物和方法 | |
| GB201615282D0 (en) | Tankyrase inhibitors | |
| IL282088A (en) | Ergoline compounds and their uses | |
| GB201608779D0 (en) | Methods and compounds | |
| HK1252428A1 (zh) | 雙環化合物及其用於抑制suv39h2的用途 | |
| GB201504763D0 (en) | Compounds and uses | |
| GB201608776D0 (en) | Methods and compounds | |
| HK1254550A1 (zh) | 用於抑制β-內酰胺酶的組合物和方法 | |
| GB201507753D0 (en) | New compounds and uses | |
| PL3183308T3 (pl) | Kompozycja do ochrony przedmiotu przed korozją | |
| GB201501593D0 (en) | New compounds and processes | |
| GB201601514D0 (en) | New processes and compounds | |
| IL258458B (en) | Peroxyhemiacetal profragrant and proflavor compounds | |
| GB201719043D0 (en) | Methods and compounds | |
| GB201621274D0 (en) | New processes and compounds | |
| GB201516922D0 (en) | New processes and compounds | |
| GB201514770D0 (en) | Compounds and their use | |
| GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors |